AVXL — Anavex Life Sciences Corp.
$0.93
$-0.06 (-5.65%)
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer.
Market Cap
$86.53M
Forward P/E
-1.7x
52-Week Range
N/A
AVXL Price History
Revenue vs. Net Income
$0
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-$39M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-48.9%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
11.6x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+2.2%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
